Athanase Competitors

Stocks . Sweden . 
Stock . Athanase Innovation AB
ATIN Stock   13.90  0.00  0.00%   
Athanase Innovation competes with Spectrumone Publ, ChargePanel, Compodium International, Scout Gaming, and JLT Mobile; as well as few others. Analyzing Athanase Innovation competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Athanase Innovation to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.

Athanase Innovation vs Divio Technologies Correlation

Poor diversification

The correlation between Athanase Innovation AB and DIVIO-B is 0.67 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Athanase Innovation AB and DIVIO-B in the same portfolio, assuming nothing else is changed.

Moving against Athanase Stock

  0.77DMYD-B Diamyd Medical ABPairCorr
  0.76EPI-B Epiroc ABPairCorr
  0.71BESQAB BesqabPairCorr
  0.7INVE-A Investor AB serPairCorr
  0.7VOLV-B AB VolvoPairCorr

Athanase Innovation Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Athanase Innovation and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Athanase and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Athanase Innovation does not affect the price movement of the other competitor.

High positive correlations

DIVIO-B
+ 0.72
ANOT
DIVIO-B
+ 0.7
COMPDM
SCOUT
+ 0.64
COMPDM
COMPDM
+ 0.58
ANOT
SCOUT
+ 0.57
ANOT
JLT
+ 0.55
ANOT
  

High negative correlations

ANOT
- 0.34
CHARGE
COMPDM
- 0.33
CHARGE
SCOUT
- 0.3
CHARGE
DIVIO-B
- 0.2
CHARGE
SONE
- 0.14
CHARGE
JLT
- 0.06
COMPDM

Risk-Adjusted Indicators

There is a big difference between Athanase Stock performing well and Athanase Innovation Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Athanase Innovation's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Athanase Innovation Competitive Analysis

The better you understand Athanase Innovation competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Athanase Innovation's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Athanase Innovation's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ATIN SPEONE CHARGE ANOT COMPDM SCOUT JLT SONE DIVIO-B
 0.00 
 13.90 
Athanase
 6.25 
 0.17 
Spectrumone
 7.43 
 1.62 
ChargePanel
 3.58 
 0.04 
Anoto
 0.57 
 3.52 
Compodium
 7.14 
 0.13 
Scout
 0.62 
 1.60 
JLT
 10.94 
 5.70 
Sonetel
 1.01 
 0.10 
Divio
Market Volatility
(90 Days Market Risk)
Slightly risky
Out of control
Extremely Dangerous
Out of control
Unstable
Out of control
Dangerous
Unstable
Out of control
Market Performance
(90 Days Performance)
Weak
Soft
Mild
Weakest
Weakest
Weak
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
High
High
High
Low
High
Low
Small
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
0.23
N/A
0.84
N/A
4.08
2.59
0.31
0.49
Net Asset
N/A
297 M
29.74 M
239.07 M
113.78 M
94.6 M
102.62 M
40.09 M
27.53 M
Profit Margin
N/A
-1.68
N/A
-0.12
-0.43
-2.61
N/A
-0.0824
-0.55
EBITDA
N/A
(110.96 M)
(4.02 M)
(18.2 M)
(15.83 M)
(60.83 M)
10.69 M
6.02 M
(5.76 M)
Operating Margin
N/A
-0.71
N/A
-0.68
-0.43
-2.51
N/A
0.0609
-0.55
Current Valuation
N/A
134.46 M
52.67 M
165.64 M
5.7 M
39.35 M
122.55 M
30.43 M
12.86 M
Price To Book
N/A
1.14
4.01
0.82
0.62
0.77
2.54
1.06
1.4
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
50 M
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
2.86
N/A
N/A
Beta
N/A
1.87
N/A
0.61
N/A
1.57
0.72
0.65
1.73
Number Of Employees
N/A
46
5
60
34
64
5
28
10
Shares Outstanding
N/A
374.22 M
16.27 M
230.61 M
10.32 M
225.2 M
28.71 M
4.42 M
158.01 M
Cash Flow From Operations
N/A
(32.45 M)
(5.91 M)
(39.02 M)
(13.44 M)
(57.36 M)
1.5 M
5.28 M
(7.23 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
0.0474
N/A
N/A
Total Debt
N/A
239 K
N/A
N/A
675 K
N/A
N/A
3.48 M
N/A
Return On Equity
N/A
-0.69
N/A
-0.14
-0.53
-0.95
0.0763
-0.0766
-0.58
Z Score
N/A
N/A
N/A
N/A
30.0
N/A
1.0
4.8
N/A
Return On Asset
N/A
-0.13
N/A
-0.15
-0.2
-0.48
0.0287
0.0197
-0.28
Book Value Per Share
N/A
0.33
N/A
0.53
7.92
4.67
2.07
5.07
0.14
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
28 M
N/A
N/A
Total Asset
N/A
297 M
29.74 M
239.07 M
113.78 M
94.6 M
102.62 M
40.09 M
27.53 M
Debt To Equity
N/A
0.067
N/A
7.7
N/A
N/A
N/A
33.2
N/A
Target Price
N/A
3.0
N/A
3.98
N/A
N/A
76.54
21.0
N/A
Shares Owned By Institutions
N/A
N/A
N/A
15.29
N/A
3.33
3.76
1.81
N/A
Market Capitalization
N/A
149.54 M
80.05 M
119.92 M
34.07 M
110.78 M
164.81 M
29.65 M
44.47 M
Price To Earning
N/A
N/A
N/A
-154.07
N/A
N/A
14.34
N/A
N/A
Price To Sales
N/A
1.71
16.57
1.24
0.71
2.17
0.93
1.13
1.0
Net Income
N/A
(154.09 M)
(4.06 M)
(33.56 M)
(23.31 M)
(71.68 M)
7.33 M
(156.94 K)
(10.88 M)
Earnings Per Share
N/A
-0.35
N/A
-0.17
N/A
-3.71
0.16
-1.92
-0.13
Shares Owned By Insiders
N/A
32.97
N/A
14.06
N/A
4.35
74.59
62.62
23.61
Revenue
N/A
60.8 M
4.07 M
71.73 M
46.77 M
31.79 M
136.17 M
21.18 M
15.7 M
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
22 M
N/A
N/A
Cash And Equivalents
N/A
30.91 M
N/A
3.88 M
N/A
49.41 M
50.1 M
856.29 K
1.09 M
Cash Per Share
N/A
0.14
N/A
0.02
N/A
2.21
1.75
0.21
0.01
Gross Profit
N/A
13.71 M
N/A
38.58 M
4.14 M
(21.31 M)
67.8 M
9.97 M
7.16 M
Day Typical Price
13.9
0.17
1.66
0.0373
3.51
0.13
1.61
5.8
0.0976
Accumulation Distribution
N/A
38215.56
4512.22
25863.22
3.95
N/A
137.0
57.65
4407.12
Market Facilitation Index
N/A
N/A
0.0
N/A
0.0
N/A
0.0
3.0E-4
N/A
Daily Balance Of Power
0.0
1.0
(0.57)
0.8125
1.0
0
(0.50)
(2.33)
0.1389
Period Momentum Indicator
N/A
0.01
(0.13)
0.0013
0.02
(0.01)
(0.01)
(0.70)
0.001
Rate Of Daily Change
1.0
1.06
0.93
1.04
1.01
0.93
0.99
0.89
1.01
Day Median Price
13.9
0.18
1.69
0.0371
3.51
0.13
1.61
5.85
0.0964
Price Action Indicator
N/A
N/A
(0.13)
0.0012
0.02
(0.01)
(0.01)
(0.50)
0.0041
Relative Strength Index
32.71
53.2
45.34
37.45
47.7
40.95
31.55
39.7
41.39
Coefficient Of Variation
(8,535)
7994.91
5191.27
(992.41)
(658.37)
8611.05
(1,061)
(1,624)
(4,788)
Mean Deviation
2.55
3.75
4.75
3.07
2.45
5.04
2.42
3.96
3.78
Jensen Alpha
(0.16)
(0.04)
0.1867
(0.32)
(0.51)
(0.12)
(0.26)
(0.26)
(0.08)
Total Risk Alpha
(0.86)
(0.63)
(0.60)
(0.81)
(0.93)
(0.84)
(0.72)
(1.04)
(1.05)
Sortino Ratio
N/A
(0)
0.0025
N/A
N/A
(0.0009)
N/A
N/A
N/A
Downside Variance
N/A
43.21
26.47
N/A
N/A
142.64
N/A
N/A
N/A
Standard Deviation
6.54
5.83
5.91
3.65
3.41
7.74
3.33
5.7
7.44
Kurtosis
9.02
5.42
0.471
(0.97)
2.7
1.32
4.02
1.01
18.96
Potential Upside
8.33
7.14
9.63
5.36
3.93
13.33
3.95
8.77
9.09
Treynor Ratio
(0.10)
0.0549
(0.11)
0.6266
2.46
0.0363
0.4712
0.3253
0.1742
Maximum Drawdown
50.44
37.19
28.86
14.19
17.62
36.86
21.71
28.29
54.23
Variance
42.82
34.0
34.94
13.33
11.63
59.93
11.08
32.54
55.31
Market Risk Adjusted Performance
(0.09)
0.0649
(0.10)
0.6366
2.47
0.0463
0.4812
0.3353
0.1842
Risk Adjusted Performance
(0.0002)
0.0183
0.0235
(0.07)
(0.11)
0.0179
(0.06)
(0.04)
(0.01)
Skewness
0.6331
1.51
0.5635
(0.02)
0.6166
(0.55)
0.9463
0.1202
3.24
Semi Deviation
N/A
3.93
4.93
N/A
N/A
6.74
N/A
N/A
N/A
Information Ratio
(0.03)
(0)
0.0022
(0.13)
(0.18)
(0)
(0.12)
(0.08)
(0.03)
Value At Risk
(7.69)
(6.25)
(8.50)
(5.53)
(5.56)
(13.33)
(4.67)
(10.94)
(9.45)
Expected Short fall
N/A
(8.32)
(5.92)
N/A
N/A
(9.32)
N/A
N/A
N/A
Downside Deviation
N/A
6.57
5.14
N/A
N/A
11.94
N/A
N/A
N/A
Semi Variance
N/A
15.48
24.26
N/A
N/A
45.43
N/A
N/A
N/A

Athanase Innovation Competition Performance Charts

Five steps to successful analysis of Athanase Innovation Competition

Athanase Innovation's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Athanase Innovation in relation to its competition. Athanase Innovation's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Athanase Innovation in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Athanase Innovation's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Athanase Innovation, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Athanase Innovation position

In addition to having Athanase Innovation in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Agency Mbs ETFs Thematic Idea Now

Agency Mbs ETFs
Agency Mbs ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Athanase Stock Analysis

When running Athanase Innovation's price analysis, check to measure Athanase Innovation's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athanase Innovation is operating at the current time. Most of Athanase Innovation's value examination focuses on studying past and present price action to predict the probability of Athanase Innovation's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athanase Innovation's price. Additionally, you may evaluate how the addition of Athanase Innovation to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY